Denial Management for Urologists

The 2026 prostate biopsy code swap is generating denials one claim at a time until templates change.

Altair Health 16 September 2026

On 1 January 2026, CPT deleted 55700, the code that covered nearly every prostate biopsy a urology practice billed, and replaced it with nine codes chosen by approach and by imaging guidance. Every superbill and EHR template still carrying 55700 has been generating denials since the first working day of the year, one claim at a time, and most of them look like every other denial on the remittance.

That is the shape of urology denials generally. A single patient episode can touch an office visit, a diagnostic cystoscopy, urodynamics, stone treatment and a surgical procedure, each under its own code rules, its own bundling edits and its own authorization requirements. The failures are not random. They concentrate in a short list of procedure families, and each one repeats until somebody fixes the thing upstream of the claim.

Cystoscopy: 52000 is a separate procedure, and no modifier unbundles it

Diagnostic cystoscopy, 52000, carries the "separate procedure" designation in CPT. Under the National Correct Coding Initiative that makes it a Column Two code against the therapeutic cystoscopy codes: biopsy at 52204, tumor resection at 52234, 52235 and 52240, stent placement at 52332, and the ureteroscopy codes 52353 and 52356. Look and treat in the same session, and only the therapeutic code pays.

The detail that catches practices is the modifier indicator. Every one of those edits carries indicator 0, which means no modifier bypasses it. Not 59, not the X modifiers. Documentation of a distinct diagnostic component does not change the outcome under Medicare's edits, because the edit does not read documentation. The correct claim carries the therapeutic code alone. A commercial payer that does not adopt NCCI may treat it differently, and that is a question for that payer's policy, not a general rule.

TURBT: the measurement in the note chooses the code

CPT codes bladder tumor resection by size. 52234 covers tumors from 0.5 to 2.0 centimeters, 52235 from 2.0 to 5.0, and 52240 above 5.0. Each descriptor reads "tumor(s)," so several small tumors do not add up to the large code. For Medicare, coding guidance selects the code by the largest tumor treated. Some commercial payers read multiple tumors differently, and the safe move is to check that payer's policy before assuming.

All of it depends on a measurement written into the operative note. A note that records "multiple bladder tumors resected" and no size gives the coder nothing to select on and gives the payer a reason to ask for records. Laterality, site, size, and a clean line between the diagnostic look and the therapeutic work, all in the note before anyone builds the claim.

The 2026 prostate biopsy codes, and the superbills still carrying 55700

The replacement family is organized around two questions: which approach, and which imaging guided it. 55705 was revised to cover biopsy without imaging guidance. 55706, transperineal stereotactic template-guided saturation biopsy, kept its descriptor but not its value: the CY 2026 Physician Fee Schedule cut its work RVUs from 6.28 to 4.16 and moved it from a 10-day global to a 0-day one, and 55705 moved to a 0-day global as well. 55707 through 55712 cover transrectal and transperineal biopsies guided by ultrasound alone or by ultrasound with MRI fusion. 55713 and 55714 cover in-bore CT- or MRI-guided biopsy, systematic plus targeted and targeted only respectively. 55715 is the add-on for each additional targeted lesion.

Imaging guidance used to ride alongside 55700 on its own line as 76872 or 76942. CPT now instructs that neither is reported with the new codes. One caution on how that reaches a claim: as of the October 2026 edit release, the NCCI procedure-to-procedure tables carry no edits at all for 55707 through 55715, so nothing denies the pairing automatically at the edit layer. A payer applying the CPT instruction will deny it on review, and a payer relying on the edit tables alone may pay it and recoup it later. Neither is a good outcome.

The fix is three template changes made together: retire 55700 from the charge master, retire 76872 and 76942 as standalone lines on biopsy encounters, and rebuild the operative note so approach and guidance method are discrete fields rather than words buried in free text.

Lithotripsy: one unit, modifier 50 for bilateral, fluoroscopy included

Extracorporeal shock wave lithotripsy, 50590, is comprehensive by design. Fluoroscopic guidance has been bundled into it under NCCI since 2003, so 76000 on a separate line fails the edit. It carries a 90-day global period. And it has a medically unlikely edit of one unit per date of service: bill two units for two kidneys and the second unit fails on arrival. Bilateral treatment in one session is one unit with modifier 50.

Laterality documentation still matters, for a different reason than the one usually given. CMS has no national rule rejecting 50590 for a missing RT or LT, but some Medicare contractors and some commercial payers do require the laterality modifier on paired-organ codes, and the operative note has to support whichever side is billed. Confirm the requirement for the payers the practice actually bills rather than applying one rule to all of them.

Repeat treatment inside the 90-day global needs the right modifier for the reason. A planned, staged second session is 58. An unplanned return for a complication is 78. Confusing the two produces a denial in one direction and an audit in the other.

Prior authorization, and what the 2026 plan exits changed

Medicare Advantage insurers made 52.8 million prior authorization determinations in 2024 and denied 4.1 million of them, or 7.7%, per KFF. Practices appealed 11.5% of those denials, and payers partially or fully overturned 80.7% of the appeals. KFF is explicit that these are service determinations rather than payment decisions on care already given: the request was denied before the service, and four in five of the denials that were challenged did not survive.

The authorization has to match what is billed: the procedure code, the technique, the device where one applies, and the rendering provider. A mismatch within the same treatment family is enough to fail the claim against an authorization that still exists on paper. Our prior authorization guide covers how those requirements differ by payer.

The 2026 plan year added a new failure point. Roughly 2.9 million Medicare Advantage enrollees, about one in ten in HMO and PPO plans, had to change plans for 2026 because their plan left the market or shrank its service area, according to a JAMA research letter. Enrollees in smaller carriers, in plans rated below four stars, and in rural counties were hit hardest. Every one of those patients arrives at the practice with authorizations issued by a plan that no longer covers them.

The rule most practices get wrong here runs the other way from what they assume. Under 42 CFR 422.112, a Medicare Advantage plan taking on a new enrollee must honor an active course of treatment for at least 90 days without requiring a new authorization. A patient mid-treatment does not need to start over. A patient starting something new does, and the new plan's requirements may differ from the old plan's on the same procedure. Knowing which patients are in which group, on the day they present, is the work.

Two more figures for the panel-mix conversation. Kodiak Solutions' 2025 data from 2,300 hospitals put Medicare Advantage initial and final denial rates at more than double those of traditional Medicare, a hospital figure, but a directional one. And the AMA's 2025 survey of 1,000 physicians found 60% concerned that payers' use of AI in authorization review is increasing denials. That is physician concern, not a measured rate, and it is worth knowing as such.

Global periods, and two 2026 changes to the prostate codes

The global surgical package bundles the pre-operative work, the procedure and the post-operative care into one payment. An unrelated evaluation and management visit inside the global period needs modifier 24. An unrelated procedure needs 79. Skip the modifier or pick the wrong one, and a legitimately separate service is denied as part of the package.

Two prostate codes moved this year in ways that raise the cost of a denial that stands. Under the CY 2026 Physician Fee Schedule, transurethral resection of the prostate, 52601, fell 25.6% on the facility side, and laser prostatectomy, 52648, fell 21.7%, the product of a work RVU revaluation and a cut to facility indirect practice expense. A medical necessity denial left uncorrected on either code costs a larger share of a smaller payment than it did a year ago.

And Aquablation moved from Category III to Category I: 52597 replaced 0421T effective 1 January 2026, with a 90-day global. A charge master still carrying 0421T rejects every Aquablation claim it produces.

Turning one denial into a process fix

Every failure above traces to a knowable upstream cause: a template, a charge master line, a note field, an authorization not matched to the claim. Resubmitting the corrected claim fixes one claim. It does nothing for the ten identical ones in the pipeline or the ten more that go out next week under the same template.

A workflow that stops the pattern draws a line between fixing the claim and fixing the process. Categorize every denial by reason, by procedure code and by payer. Correct the claim in front of you. Then feed what it taught back into the template, the scrub or the authorization checklist that produced it. Denial rate by procedure code shows where the money leaves. Denial rate by payer shows a policy change before it becomes the new baseline. Appeal success rate separates the recoverable from the ones that need an upstream fix instead of another letter. Our denial code reference covers what each CARC requires, and our claims scrubbing guide covers what a complete pre-submission check includes.

Altair runs eligibility verification, authorization tracking, claim scrubbing against each payer's current policies, denial work and appeals, and keeps what it learns about each payer in the system rather than in a person. Coding stays with the practice's own coders. Altair's in-house billers own the exceptions the automation should not decide, and the practice keeps the EMR and clearinghouse it already uses. See how Altair runs denial management.

The urology practices losing the least to denials in 2026 are not the ones with the best appeal letters. They are the ones whose superbills stopped carrying 55700 in January.

What changed in the 2026 code set

Common questions